Results 251 to 260 of about 766,818 (299)

Harmonizing the Pyrene and Ether Groups in Covalent Triazine Polymers for Highly Effective H2O2 Photosynthesis via One‐Step Two‐Electron Oxygen Reduction

Advanced Functional Materials, EarlyView.
The pyrene and ether groups are incorporated into the covalent triazine polymer (CTP) structure. The synergistic effect of the two functional groups endows CTP with better electron transfer, light absorption, and oxygen activation properties. An impressive apparent quantum yield (13.2% @420 nm) and a remarkable solar‐to‐chemical conversion efficiency ...
Chong Wang, Jinliang Lv, Yichun Lu, Hanfeng Ye, Xuan Zhang, Leonardo Cancellara, Nadezda Tarakina, Jiande Lin, Xin Gao, Oleksandr Savateev, Jiajia Cheng   +10 more
wiley   +1 more source

Chimeric PD‑1 receptor redirects primary T cells against childhood solid tumors but not to PD‑1 ligand‑positive CD80‑coexpressing cells. [PDF]

Mol Med Rep
Shin C, Imamura M, Kasahara Y, Suzuki Y, Baba M, Kubo N, Hosokai R, Iwabuchi H, Murayama Y, Kawashima H, Ogose A, Mihara K, Saitoh A, Imai C.   +13 more
europepmc   +1 more source

Ligand-receptor interaction profiling as a predictive biomarker for anti-PD-1 therapy response in melanoma. [PDF]

Clin Exp Med
Seo SY, Nam DY, Lee HJ, Rhee JK.
europepmc   +1 more source

The PD-1/PD-L1 pathway and Epstein-Barr virus. [PDF]

Eur J Med Res
Wang H, Zhang N, Xu R, Ji C, Wei Y, Mi Q.   +5 more
europepmc   +1 more source

Synergistic antitumor efficacy of CIK cells combined with PD-1 inhibitors in nasopharyngeal carcinoma. [PDF]

Am J Transl Res
Chen J, Sailihan T, Chen Y, Xv S, Qian J, Shen X, Yang H, Zhang P.   +7 more
europepmc   +1 more source

Editorial: Response/resistance to PD-1 axis inhibitors: focus on the tumor microenvironment. [PDF]

Front Immunol
Fazeli P, Yaghoubi D, Vathiotis I, Kulasinghe A, Aung TN.   +4 more
europepmc   +1 more source

Nanobody Nb07 mitigates sepsis by blocking the PFKM-p53-PD-1 axis to enhance macrophage phagocytosis. [PDF]

Theranostics
Ji B, Guo H, Xing R, Sun M, Cheng Y, Yao C, Zhu H, Wang X, Jiang R, Chen X, Liu Z, Wang S, Xu F, Zhang F, Dong F, Pan X, Yang J, Pan Y.   +17 more
europepmc   +1 more source

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma [PDF]

Nature Medicine, 2019
Glioblastoma is the most common primary malignant brain tumor in adults and is associated with poor survival. The Ivy Foundation Early Phase Clinical Trials Consortium conducted a randomized, multi-institution clinical trial to evaluate immune responses ...
Timothy Cloughesy, Aaron Y Mochizuki, Joey R Orpilla   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

PD-1 and Autoimmunity

Critical Reviews™ in Immunology, 2011
An initiating T cell response requires both costimulatory signaling and T cell receptor/MHC binding. The immune system balances positive and negative costimulatory signal pathways to activate and deactivate T cells. This review focuses primarily on PD-1 and its ligands, which form a crucial inhibitory costimulatory pathway for maintaining peripheral ...
Shimpei, Kasagi, Seiji, Kawano, Shunichi, Kumagai   +2 more
openaire   +2 more sources

Nanobodies targeting the interaction interface of programmed death receptor 1 (PD-1)/PD-1 ligand 1 (PD-1/PD-L1)

Preparative Biochemistry & Biotechnology, 2019
Targeting the interaction interface is an effective strategy to obtain programmed death receptor 1 (PD-1)/PD-1 ligand 1 (PD-L1) nanobody blockers. To validate this strategy, the interaction interface between PD-1 and the PD-L1 extracellular domain were analyzed using Cn3D 4.1. The peptide PD-1125-136 located at the interface of PD-1 was selected as the
Biyan, Wen, Lin, Zhao, Yuchu, Wang, Chuangnan, Qiu, Zhimin, Xu, Kunling, Huang, He, Zhu, Zemin, Li, Huangjin, Li   +8 more
openaire   +2 more sources